The Sponsor may decide to limit the specific tumor types selected or treatment settings for specific arms based on evidence gathered.
Are pregnant or breast-feeding patients or any patient with childbearing potential not using adequate pregnancy prevention (site-specific criteria applying to Avera only)
Specific medications
Subjects above specific amount of serum creatinine.
Specific mutations:
Patients must not be receiving any additional medicines being given for the specific purpose of treating cancer
patients with a histologically confirmed diagnosis of select advanced, unresectable, and/or metastatic solid tumours with specific histology/tumour types and/or specific genetic profiles
Unable to generate antigen-specific WT-specific CD+ T cells for infusions; however, if a lower than planned number of cells is available, the patient will have the option to receive the generated WT-specific T cells
STUDY-SPECIFIC EXCLUSIONS:
STUDY-SPECIFIC EXCLUSIONS:
Available multivirus-specific VSTs
Patients treated with biologics within a specific timeframe
Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR
Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR
Unable to generate antigen-specific WT-specific CD+ T cells for infusions; however, the patient will have the option to receive WT-specific T-cells if a lower than planned number of cells is available
Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR
Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR
DISEASE-SPECIFIC EXCLUSIONS:
BEVACIZUMAB-SPECIFIC EXCLUSIONS:
BEVACIZUMAB-SPECIFIC EXCLUSIONS
Unable to generate antigen-specific MCPyV TAg-specific CD+ T cells for infusions
Participants medicated with anti-depressants reported to have lysine-specific histone demethylase A (KDMA)/lysine (K)-specific demethylase A (LSD) inhibitory activity (such as tranylcypromine or phenelzine) within  days of treatment start
Using a consistent and daily amount of ST with specific nicotine and tobacco-specific nitrosamine (TSNA) levels for the past year;
Must give study specific informed consent prior to enrollment. For re-administration, patients must be re-consented.
Patients for whom we are unable to generate NY-ESO- specific cells
BEVACIZUMAB-SPECIFIC EXCLUSIONS
Chronic daily treatment with a nonsteroidal anti-inflammatory drug (NSAID) Exclusions specific to Arms A and F (HCC) (Patients who meet any of the following specific exclusion criteria will be excluded from enrollment in Arms A and F:)
Available multivirus-specific CTLs
SPECIFIC TO STUDY PART #
SPECIFIC TO STUDY PART #
Other malignancy diagnosed or requiring treatment within the defined period with specific exceptions
Has a study site-specific nurse available to act as a PN or has a (study site-specific or shared) nurse available to act as a clinical consultant to a study site-specific, non-nurse navigator\r\n* Study sites randomized to the Intervention Arm are not eligible to register subjects (nor administer the protocol intervention), until the sites identified PN(s) has/have completed the protocol-specific navigation training
Specific serum electrolyte levels